If you smoke and want to quit, call the national quit line at 1-800-784-8669 to speak with a confidential coach. In what ...

Wendy Brooks, a survivor of extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, spoke ...

Results showed tarlatamab significantly reduced the risk of death by 40% vs standard of care treatment (HR, 0.60 [95% CI, 0.47-0.77]; P .001). The Food and Drug Administration (FDA) has granted ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab extended PFS and OS. A higher percentage of patients assigned the ...

PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall survival or progression-free ...

Doctors typically divide small cell lung cancer (SCLC) into limited or extensive stages, depending on whether the cancer is in one lung, both lungs, or has spread to distant areas. Staging for small ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) ...

The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who have ...

The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer. Lurbinectedin (Zepzelca; Jazz Pharmaceuticals, PharmaMar) is ...

Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Daiichi Sankyo and Merck Launch New Lung Cancer Study With ...

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...